Stockpolly
Search
SVRA · NASDAQ · Biotechnology

Savara (SVRA)

Developing inhaled MOLBREEVI for autoimmune pulmonary alveolar proteinosis.

$5.50
Pre-market+0.04 (+0.73%)
At close$5.46(+2.06%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue140112001021000
Gross profit−140−1−1−200−10−21000
4182123631283110333941
Research & development141317182023192121212322
45666891110131619
General & administrative45666091110131619
Other expenses−140−1−1−200−10−21000
Operating income−18−18−22−23−26−31−28−31−30−33−39−41
122122211121
Interest income121122111111
Other non-operating income0−2−1−1−2−2−1−1−1−1−2−1
Income before tax−17−16−20−22−24−29−27−30−30−32−37−40
Net income from continuing operations−17−16−20−22−24−29−27−30−30−32−37−40
Net income−17−16−20−22−24−29−27−30−30−32−37−40
EPS, basic−$0.10−$0.09−$0.11−$0.12−$0.11−$0.14−$0.12−$0.14−$0.14−$0.13−$0.15−$0.16
EPS, diluted−$0.10−$0.09−$0.11−$0.12−$0.11−$0.14−$0.12−$0.14−$0.14−$0.13−$0.15−$0.16
Weighted average shares, basic164180183183212198216216216222253254
Weighted average shares, diluted164180183183212198216216216222253254
EBITDA−18−16−22−22−24−29−28−30−29−32−37−40
Depreciation & amortization000000000000
EBIT−18−16−22−22−24−29−28−30−30−32−37−40